Drug Trial Radar · NCT06220318
Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
155
Planned (sponsor's estimate)
Start
Jul 19, 2023
Primary completion
Aug 30, 2026
Study completion Aug 30, 2026
Sponsor
- Lead sponsor
- Fujian Haixi Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/II non-randomized, open-label, single-arm, multicenter study to evaluate the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors.
Conditions
- Solid Tumor
Interventions
C019199Drug
The C019199 will be taken orally, once a day
SintilimabDrug
Sintilimab will be administrated with intravenous infusion, 200mg, every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicity (DLT)Time frame: Cycle 1 (Cycle length=21 days)
- Objective Response Rate (ORR) Based on iRECISTTime frame: From date of enrollment until the date of first documented progression or death
- Progression-free Survival (PFS) after administrationTime frame: From date of enrollment until the date of first documented progression or death
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Hunan Cancer Hospital
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.